Czech Republic In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

Company’s new report, “Czech Republic In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Czech Republic In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Czech Republic In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, bioMerieux S.A., Beckman Coulter, Inc., Becton, Dickinson and Company and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Czech Republic In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
 

1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 14
2.1 What is This Report About? 14
3 In Vitro Diagnostics In Czech Republic 15
3.1 In Vitro Diagnostics, Market Segmentation 15
3.2 In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, 2003-2017 16
3.3 In Vitro Diagnostics Market, Czech Republic, Revenue Mix ($m), 2010 18
3.4 In Vitro Diagnostics Market, Czech Republic, Category Contribution (%), 2010 19
3.5 In Vitro Diagnostics, Czech Republic, Company share (2009-2010) 26
4 Clinical Chemistry In Czech Republic 28
4.1 Clinical Chemistry, Market Segmentation 28
4.2 Clinical Chemistry Market, Czech Republic, Revenue Mix ($m), 2010 29
4.3 Clinical Chemistry Market, Czech Republic, Segment Contribution (%), 2010 30
4.4 Clinical Chemistry Overall Revenue (2003-2017) 31
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 35
4.4.2 Urine Analysis Revenue (2003-2017) 39
4.5 Clinical Chemistry Distribution Share (2009-2010) 43
4.6 Clinical Chemistry, Czech Republic, Company share (2009-2010) 44
5 Genetic Testing In Czech Republic 46
5.1 Genetic Testing, Market Segmentation 46
5.2 Genetic Testing Market, Czech Republic, Revenue Mix ($m), 2010 47
5.3 Genetic Testing Market, Czech Republic, Segment Contribution (%), 2010 48
5.4 Genetic Testing Overall Revenue (2003-2017) 49
5.5 Genetic Testing Distribution Share (2009-2010) 53
5.6 Genetic Testing, Czech Republic, Company share (2009-2010) 54
6 Haematology In Czech Republic 56
6.1 Haematology, Market Segmentation 56
6.2 Haematology Market, Czech Republic, Revenue Mix ($m), 2010 57
6.3 Haematology Market, Czech Republic, Segment Contribution (%), 2010 58
6.4 Haematology Overall Revenue (2003-2017) 59
6.4.1 Haematology Reagents Revenue (2003-2017) 63
6.4.2 Immunohaematology Revenue (2003-2017) 67
6.4.3 Haemostasis Revenue (2003-2017) 71
6.4.4 Haematology Rapid Tests Revenue (2003-2017) 75
6.4.5 Haematology Cell Counters Revenue (2003-2017) 79
6.5 Haematology Distribution Share (2009-2010) 83
6.6 Haematology, Czech Republic, Company share (2009-2010) 84
7 Histology And Cytology In Czech Republic 86
7.1 Histology And Cytology, Market Segmentation 86
7.2 Histology And Cytology Market, Czech Republic, Revenue Mix ($m), 2010 87
7.3 Histology And Cytology Market, Czech Republic, Segment Contribution (%), 2010 88
7.4 Histology And Cytology Overall Revenue (2003-2017) 89
7.5 Histology And Cytology Distribution Share (2009-2010) 93
7.6 Histology And Cytology, Czech Republic, Company share (2009-2010) 94
8 Immuno Chemistry In Czech Republic 96
8.1 Immuno Chemistry Market, Czech Republic, Revenue Mix ($m), 2010 96
8.2 Immuno Chemistry Market, Czech Republic, Segment Contribution (%), 2010 97
8.3 Immuno Chemistry Overall Revenue (2003-2017) 98
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 102
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 106
8.3.3 Endocrinology Tests Revenue (2003-2017) 110
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 114
8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 118
8.4 Immuno Chemistry Distribution Share (2009-2010) 122
8.5 Immuno Chemistry, Czech Republic, Company share (2009-2010) 123
9 Infectious Immunology In Czech Republic 125
9.1 Infectious Immunology, Market Segmentation 125
9.2 Infectious Immunology Market, Czech Republic, Revenue Mix ($m), 2010 126
9.3 Infectious Immunology Market, Czech Republic, Segment Contribution (%), 2010 127
9.4 Infectious Immunology Overall Revenue (2003-2017) 128
9.5 Infectious Immunology Distribution Share (2009-2010) 132
9.6 Infectious Immunology, Czech Republic, Company share (2009-2010) 133
10 Microbiology Culture In Czech Republic 135
10.1 Microbiology Culture, Market Segmentation 135
10.2 Microbiology Culture Market, Czech Republic, Revenue Mix ($m), 2010 136
10.3 Microbiology Culture Market, Czech Republic, Segment Contribution (%), 2010 137
10.4 Microbiology Culture Overall Revenue (2003-2017) 138
10.4.1 Microbiology Analyzers Revenue (2003-2017) 142
10.5 Microbiology Culture Distribution Share (2009-2010) 146
10.6 Microbiology Culture, Czech Republic, Company share (2009-2010) 147
11 Overview of Key Companies in Czech Republic In Vitro Diagnostics Market 149
11.1 F. Hoffmann-La Roche Ltd. 149
11.1.1 Company Overview 149
11.1.2 Share in the Czech Republic In Vitro Diagnostics Market 149
11.2 Siemens Healthcare 150
11.2.1 Company Overview 150
11.2.2 Share in the Czech Republic In Vitro Diagnostics Market 150
11.3 Abbott Laboratories 151
11.3.1 Company Overview 151
11.3.2 Share in the Czech Republic In Vitro Diagnostics Market 151
11.4 bioMerieux S.A. 152
11.4.1 Company Overview 152
11.4.2 Share in the Czech Republic In Vitro Diagnostics Market 152
11.5 Beckman Coulter, Inc. 153
11.5.1 Company Overview 153
11.5.2 Share in the Czech Republic In Vitro Diagnostics Market 153
11.6 Becton, Dickinson and Company 154
11.6.1 Company Overview 154
11.6.2 Share in the Czech Republic In Vitro Diagnostics Market 154
11.7 Bio-Rad Laboratories, Inc. 155
11.7.1 Company Overview 155
11.8 Ortho-Clinical Diagnostics Inc. 155
11.8.1 Company Overview 155
11.9 Sysmex Corporation 155
11.9.1 Company Overview 155
11.10 DiaSorin S.p.A 156
11.10.1 Company Overview 156
11.11 Phadia AB 156
11.11.1 Company Overview 156
11.12 Alere Inc. 156
11.12.1 Company Overview 156
11.13 Qiagen N.V. 157
11.13.1 Company Overview 157
11.14 PerkinElmer, Inc. 157
11.14.1 Company Overview 157
11.15 Gen-Probe Incorporated 157
11.15.1 Company Overview 157
11.16 Danaher Corporation 158
11.16.1 Company Overview 158
11.17 DIAGNOSTICA STAGO, Inc. 158
11.17.1 Company Overview 158
11.18 HORIBA, Ltd. 158
11.18.1 Company Overview 158
11.19 Thermo Fisher Scientific Inc. 159
11.19.1 Company Overview 159
11.20 Cellestis Limited 159
11.20.1 Company Overview 159
11.21 Hologic, Inc. 160
11.21.1 Company Overview 160
11.22 Life Technologies Corporation 160
11.22.1 Company Overview 160
11.23 Grifols, S.A. 161
11.23.1 Company Overview 161
11.24 Immucor, Inc. 161
11.24.1 Company Overview 161
12 In Vitro Diagnostics Market Pipeline Products 162
12.1 Clinical Chemisty Market Pipeline Products 162
12.2 Immuno Chemistry Market Pipeline Products 165
12.3 Haematology Market Pipeline Products 168
12.4 Infectious Immunology Market Pipeline Products 170
12.5 Microbiology Culture Market Pipeline Products 173
12.6 Histology And Cytology Market Pipeline Products 174
12.7 Genetic Testing Market Pipeline Products 175
13 Financial Deals Landscape 178
13.1 Partnerships 178
13.1.1 Biofortuna Enters Into Distribution Agreement With Abbott 178
13.1.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 179
14 Appendix 180
14.1 Definitions of Markets Covered in the Report 181
14.1.1 In Vitro Diagnostics 181
14.2 Research Methodology 192
14.3 Secondary Research 192
14.4 Primary Research 192
14.5 Models 193
14.6 Forecasts 194
14.7 Expert Panels 194
14.8 Company Consulting 194
14.9 Currency Conversion 195
14.10 Contact Us 195
14.11 Disclaimer 195

1.1 List of Tables

Table 1: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, 2003-2017 17
Table 2: In Vitro Diagnostics Market, Czech Republic, Category Contribution (%), 2010 19
Table 3: In Vitro Diagnostics, Czech Republic, Cross-Category Analysis, 2003-2017 21
Table 4: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, Historic, 2003-2010 23
Table 5: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 25
Table 6: In Vitro Diagnostics, Czech Republic, Company share by Revenue ($m), USD Actual, 2009-2010 27
Table 7: Clinical Chemistry Market, Czech Republic, Segment Contribution (%), 2010 30
Table 8: Clinical Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 32
Table 9: Clinical Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 34
Table 10: Clinical Chemisty Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 36
Table 11: Clinical Chemisty Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 38
Table 12: Urine Analysis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 40
Table 13: Urine Analysis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 42
Table 14: Clinical Chemistry, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 15: Clinical Chemistry, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 45
Table 16: Genetic Testing Market, Czech Republic, Segment Contribution (%), 2010 48
Table 17: Genetic Testing, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 50
Table 18: Genetic Testing, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 52
Table 19: Genetic Testing, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 53
Table 20: Genetic Testing, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 55
Table 21: Haematology Market, Czech Republic, Segment Contribution (%), 2010 58
Table 22: Haematology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 60
Table 23: Haematology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 62
Table 24: Haematology Reagents, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 64
Table 25: Haematology Reagents, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 66
Table 26: Immunohaematology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 68
Table 27: Immunohaematology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 70
Table 28: Haemostasis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 72
Table 29: Haemostasis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 74
Table 30: Haematology Rapid Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 76
Table 31: Haematology Rapid Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 78
Table 32: Haematology Cell Counters, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Table 33: Haematology Cell Counters, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Table 34: Haematology, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 83
Table 35: Haematology, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 85
Table 36: Histology And Cytology Market, Czech Republic, Segment Contribution (%), 2010 88
Table 37: Histology And Cytology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 90
Table 38: Histology And Cytology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 92
Table 39: Histology And Cytology, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 93
Table 40: Histology And Cytology, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 95
Table 41: Immuno Chemistry Market, Czech Republic, Segment Contribution (%), 2010 97
Table 42: Immuno Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 99
Table 43: Immuno Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 101
Table 44: Disease Specific Immunochemistry, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 103
Table 45: Disease Specific Immunochemistry, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 105
Table 46: Drugs of Abuse / Toxicology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 107
Table 47: Drugs of Abuse / Toxicology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 109
Table 48: Endocrinology Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 111
Table 49: Endocrinology Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 113
Table 50: Therapeutic Drug Monitoring, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115
Table 51: Therapeutic Drug Monitoring, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117
Table 52: Immunochemistry Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 119
Table 53: Immunochemistry Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 121
Table 54: Immuno Chemistry, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 55: Immuno Chemistry, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 124
Table 56: Infectious Immunology Market, Czech Republic, Segment Contribution (%), 2010 127
Table 57: Infectious Immunology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 129
Table 58: Infectious Immunology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 131
Table 59: Infectious Immunology, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 132
Table 60: Infectious Immunology, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 134
Table 61: Microbiology Culture Market, Czech Republic, Segment Contribution (%), 2010 137
Table 62: Microbiology Culture, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 139
Table 63: Microbiology Culture, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 141
Table 64: Microbiology Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 143
Table 65: Microbiology Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 145
Table 66: Microbiology Culture, Czech Republic, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 67: Microbiology Culture, Czech Republic, Company share by Revenue ($m), USD Actual 2009-2010 148
Table 68: Clinical Chemisty Market Pipeline Products 162
Table 69: Immuno Chemistry Market Pipeline Products 165
Table 70: Haematology Market Pipeline Products 168
Table 71: Infectious Immunology Market Pipeline Products 170
Table 72: Microbiology Culture Market Pipeline Products 173
Table 73: Histology And Cytology Market Pipeline Products 174
Table 74: Genetic Testing Market Pipeline Products 175
Table 75: Biofortuna Enters Into Distribution Agreement With Abbott 178
Table 76: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 179
Table 77: USD to Local Currency, Czech Republic, Average Actual Rate 2003-2010 195

1.2 List of Figures

Figure 1: In Vitro Diagnostics, Market Segmentation 15
Figure 2: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, 2003-2017 16
Figure 3: In Vitro Diagnostics Market, Czech Republic, Revenue Mix ($m), 2010 18
Figure 4: In Vitro Diagnostics Market, Czech Republic, Category Contribution (%), 2010 19
Figure 5: In Vitro Diagnostics, Czech Republic, Cross-Category Analysis, 2003-2017 20
Figure 6: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, Historic, 2003-2010 22
Figure 7: In Vitro Diagnostics, Czech Republic, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 24
Figure 8: In Vitro Diagnostics, Czech Republic, Company share (%), 2010 26
Figure 9: Clinical Chemistry, Market Segmentation 28
Figure 10: Clinical Chemistry Market, Czech Republic, Revenue Mix ($m), 2010 29
Figure 11: Clinical Chemistry Market, Czech Republic, Segment Contribution (%), 2010 30
Figure 12: Clinical Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 31
Figure 13: Clinical Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 33
Figure 14: Clinical Chemisty Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 35
Figure 15: Clinical Chemisty Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 37
Figure 16: Urine Analysis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 39
Figure 17: Urine Analysis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 41
Figure 18: Clinical Chemistry, Czech Republic, Company share (%), 2010 44
Figure 19: Genetic Testing, Market Segmentation 46
Figure 20: Genetic Testing Market, Czech Republic, Revenue Mix ($m), 2010 47
Figure 21: Genetic Testing Market, Czech Republic, Segment Contribution (%), 2010 48
Figure 22: Genetic Testing, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 49
Figure 23: Genetic Testing, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 51
Figure 24: Genetic Testing, Czech Republic, Company share (%), 2010 54
Figure 25: Haematology, Market Segmentation 56
Figure 26: Haematology Market, Czech Republic, Revenue Mix ($m), 2010 57
Figure 27: Haematology Market, Czech Republic, Segment Contribution (%), 2010 58
Figure 28: Haematology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 59
Figure 29: Haematology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 61
Figure 30: Haematology Reagents, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 63
Figure 31: Haematology Reagents, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 65
Figure 32: Immunohaematology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 67
Figure 33: Immunohaematology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 69
Figure 34: Haemostasis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 71
Figure 35: Haemostasis, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 73
Figure 36: Haematology Rapid Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 75
Figure 37: Haematology Rapid Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 77
Figure 38: Haematology Cell Counters, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 79
Figure 39: Haematology Cell Counters, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 81
Figure 40: Haematology, Czech Republic, Company share (%), 2010 84
Figure 41: Histology And Cytology, Market Segmentation 86
Figure 42: Histology And Cytology Market, Czech Republic, Revenue Mix ($m), 2010 87
Figure 43: Histology And Cytology Market, Czech Republic, Segment Contribution (%), 2010 88
Figure 44: Histology And Cytology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 89
Figure 45: Histology And Cytology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 91
Figure 46: Histology And Cytology, Czech Republic, Company share (%), 2010 94
Figure 47: Immuno Chemistry Market, Czech Republic, Revenue Mix ($m), 2010 96
Figure 48: Immuno Chemistry Market, Czech Republic, Segment Contribution (%), 2010 97
Figure 49: Immuno Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 98
Figure 50: Immuno Chemistry, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 100
Figure 51: Disease Specific Immunochemistry, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 102
Figure 52: Disease Specific Immunochemistry, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 104
Figure 53: Drugs of Abuse / Toxicology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 106
Figure 54: Drugs of Abuse / Toxicology, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 108
Figure 55: Endocrinology Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 110
Figure 56: Endocrinology Tests, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 112
Figure 57: Therapeutic Drug Monitoring, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
Figure 58: Therapeutic Drug Monitoring, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
Figure 59: Immunochemistry Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 118
Figure 60: Immunochemistry Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 120
Figure 61: Immuno Chemistry, Czech Republic, Company share (%), 2010 123
Figure 62: Infectious Immunology, Market Segmentation 125
Figure 63: Infectious Immunology Market, Czech Republic, Revenue Mix ($m), 2010 126
Figure 64: Infectious Immunology Market, Czech Republic, Segment Contribution (%), 2010 127
Figure 65: Infectious Immunology, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 128
Figure 66: Infectious Immunology, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 130
Figure 67: Infectious Immunology, Czech Republic, Company share (%), 2010 133
Figure 68: Microbiology Culture, Market Segmentation 135
Figure 69: Microbiology Culture Market, Czech Republic, Revenue Mix ($m), 2010 136
Figure 70: Microbiology Culture Market, Czech Republic, Segment Contribution (%), 2010 137
Figure 71: Microbiology Culture, Czech Republic, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 138
Figure 72: Microbiology Culture, Czech Republic, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 140
Figure 73: Microbiology Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 142
Figure 74: Microbiology Analyzers, Czech Republic, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 144
Figure 75: Microbiology Culture, Czech Republic, Company share (%), 2010 147
Figure 76: F. Hoffmann-La Roche Ltd., Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 149
Figure 77: Siemens Healthcare, Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 150
Figure 78: Abbott Laboratories, Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 151
Figure 79: bioMerieux S.A., Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 152
Figure 80: Beckman Coulter, Inc., Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 153
Figure 81: Becton, Dickinson and Company, Company Share (%),Czech Republic In Vitro Diagnostics Market, 2010 154

Companies Mentioned :

F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
bioMerieux S.A.
Beckman Coulter, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Ortho-Clinical Diagnostics Inc.
Sysmex Corporation
DiaSorin S.p.A
Phadia AB
Alere Inc.
Qiagen N.V.
PerkinElmer, Inc.
Gen-Probe Incorporated
Danaher Corporation
DIAGNOSTICA STAGO, Inc.
HORIBA, Ltd.
Thermo Fisher Scientific Inc.
Cellestis Limited
Hologic, Inc.
Life Technologies Corporation
Grifols, S.A.
Immucor, Inc.